Fasinumab

Generic Name: Fasinumab

Drug Type: Biotech

CAS Number: 1190239-42-9

Unique Ingredient Identifier: 11T51Q3082

Background: Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population.

NGF was first discovered in the 1950s and was the first neurotrophic factor to be identified and biochemically characterized. It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

Clinical Trials

FDA Reviews Pfizer and Lilly's Tanezumab for Osteoarthritis Pain

5 months ago

• The FDA has begun its review of tanezumab, a non-opioid painkiller developed by Pfizer and Eli Lilly, for treating chronic pain associated with moderate-to-severe osteoarthritis. • Tanezumab, an NGF inhibitor, aims to provide relief for patients who do not respond adequately to other analgesic drugs, addressing a significant unmet need. • Clinical trials have shown tanezumab to be generally well-tolerated, though concerns remain regarding rapidly progressing joint destruction, a known risk with NGF inhibitors. • The FDA's decision, following a standard 10-month review and an advisory committee meeting, is expected in December, potentially offering a new option for millions of osteoarthritis sufferers.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy